# Milestone Scientific Inc.: overview MLSS · NYSE · CIK 855683 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mlss.md) · [Financials](/companies/mlss/financials.md) · [Filings](/companies/mlss/filings.md) · [Insiders](/companies/mlss/insiders.md) Latest reported revenue: [$2.8m](/filings/0001493152-26-037761.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001493152-26-037761). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [2,514](/filings/0001493152-25-022276.md) | [2,014 d](/filings/0001493152-26-014117.md) | [2,232](/filings/0001493152-26-022701.md) | [2,323](/filings/0001493152-26-037761.md) | [2,360](/filings/0001493152-25-022276.md) | [2,058 d](/filings/0001493152-26-014117.md) | [2,162](/filings/0001493152-26-022701.md) | [2,841](/filings/0001493152-26-037761.md) | | Gross margin | % | [73.0%](/filings/0001493152-25-022276.md) | [75.0% d](/filings/0001493152-26-014117.md) | [73.8%](/filings/0001493152-26-022701.md) | [69.6%](/filings/0001493152-26-037761.md) | [69.5%](/filings/0001493152-25-022276.md) | [73.0% d](/filings/0001493152-26-014117.md) | [72.3%](/filings/0001493152-26-022701.md) | [67.2%](/filings/0001493152-26-037761.md) | | Operating margin | % | [(58.4%)](/filings/0001493152-25-022276.md) | [(101.4%) d](/filings/0001493152-26-014117.md) | [(89.5%)](/filings/0001493152-26-022701.md) | [(63.9%)](/filings/0001493152-26-037761.md) | [(48.1%)](/filings/0001493152-25-022276.md) | [(52.5%) d](/filings/0001493152-26-014117.md) | [(38.3%)](/filings/0001493152-26-022701.md) | [(37.4%)](/filings/0001493152-26-037761.md) | | Net margin | % | [(58.1%)](/filings/0001493152-25-022276.md) | [(101.1%) d](/filings/0001493152-26-014117.md) | [(89.3%)](/filings/0001493152-26-037761.md) | [(63.8%)](/filings/0001493152-26-037761.md) | [(48.9%)](/filings/0001493152-25-022276.md) | [(53.0%) d](/filings/0001493152-26-014117.md) | [(38.8%)](/filings/0001493152-26-037761.md) | [(37.3%)](/filings/0001493152-26-037761.md) | | Diluted EPS | $ per share | [(0.02)](/filings/0001493152-25-022276.md) | not reported | [(0.02)](/filings/0001493152-26-022701.md) | [(0.02)](/filings/0001493152-26-037761.md) | [(0.01)](/filings/0001493152-25-022276.md) | not reported | [(0.01)](/filings/0001493152-26-022701.md) | [(0.01)](/filings/0001493152-26-037761.md) | | Free cash flow | $k | not reported | [(1,515) d](/filings/0001493152-26-014117.md) | [(1,009)](/filings/0001493152-26-022701.md) | [(1,769) d](/filings/0001493152-26-037761.md) | [75.5 d](/filings/0001493152-25-022276.md) | [(229) d](/filings/0001493152-26-014117.md) | [85.2](/filings/0001493152-26-022701.md) | [(589) d](/filings/0001493152-26-037761.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [10.3](/filings/0001437749-23-008658.md) | [8.8](/filings/0001437749-24-010029.md) | [9.8](/filings/0001437749-25-012050.md) | [8.6](/filings/0001493152-26-014117.md) | [9.0](/filings/0001493152-26-014117.md) | | Gross margin | % | [61.3%](/filings/0001437749-23-008658.md) | [55.7%](/filings/0001437749-24-010029.md) | [69.1%](/filings/0001437749-25-012050.md) | [74.6%](/filings/0001493152-26-014117.md) | [71.4%](/filings/0001493152-26-014117.md) | | Operating margin | % | [(71.6%)](/filings/0001437749-23-008658.md) | [(100.2%)](/filings/0001437749-24-010029.md) | [(72.3%)](/filings/0001437749-25-012050.md) | [(78.3%)](/filings/0001493152-26-014117.md) | [(63.5%)](/filings/0001493152-26-014117.md) | | Net margin | % | [(66.2%)](/filings/0001437749-23-008658.md) | [(98.9%)](/filings/0001437749-24-010029.md) | [(70.5%)](/filings/0001437749-25-012050.md) | [(54.6%)](/filings/0001493152-26-014117.md) | [(63.8%)](/filings/0001493152-26-014117.md) | | Diluted EPS | $ per share | [(0.10)](/filings/0001437749-22-007873.md) | not reported | not reported | [(0.06)](/filings/0001493152-26-014117.md) | [(0.07)](/filings/0001493152-26-014117.md) | | Free cash flow | $m | [(4.0)](/filings/0001437749-23-008658.md) | [(6.0)](/filings/0001437749-24-010029.md) | not reported | [(2.9)](/filings/0001493152-26-014117.md) | [(2.9)](/filings/0001493152-26-014117.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mlss/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $665.5k | 2,073,166 | | Added +86,518 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $206.7k | 643,611 | | Added +26,966 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $149.1k | 464,449 | | Added +142,866 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $85.0k | 264,885 | | Added +125,000 | | [NFSG Corp](/funds/1879757.md) | 2026-06-30 | $45.3k | 141,000 | | Added +100,000 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $42.7k | 133,067 | | Added +20,452 | | [LPL Financial LLC](/funds/1403438.md) | 2026-06-30 | $40.1k | 124,945 | | Unchanged | | [Mariner, LLC](/funds/1373442.md) | 2026-06-30 | $39.1k | 121,750 | | Unchanged | | [Carnegie Investment Counsel](/funds/1511506.md) | 2026-06-30 | $32.2k | 100,175 | | Unchanged | | [BRIDGEWAY CAPITAL MANAGEMENT, LLC](/funds/1107261.md) | 2026-06-30 | $31.9k | 99,500 | | Unchanged | ## Recent filings [All 513 filings](/companies/mlss/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-13 | 16:10 ET | [10-Q](/filings/0001493152-26-037761.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037761 | | 2026-07-31 | 11:50 ET | [8-K](/filings/0001493152-26-035574.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001493152-26-035574 | | 2026-07-29 | 17:28 ET | [8-K](/filings/0001493152-26-035264.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-035264 | | 2026-06-25 | 09:00 ET | [8-K](/filings/0001493152-26-030044.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-030044 | | 2026-06-22 | 14:26 ET | [DEF 14A](/filings/0001493152-26-029558.md) | Proxy statement, period 2026-06-22 | 0001493152-26-029558 | | 2026-05-13 | 16:00 ET | [10-Q](/filings/0001493152-26-022701.md) | Quarterly report, period 2026-03-31 | 0001493152-26-022701 | | 2026-05-06 | 16:56 ET | [8-K](/filings/0001493152-26-021512.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001493152-26-021512 | | 2026-05-06 | 16:47 ET | [8-K](/filings/0001493152-26-021506.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-021506 | | 2026-05-05 | 16:01 ET | [10-K/A](/filings/0001493152-26-021293.md) | Annual report, amended, period 2025-12-31 | 0001493152-26-021293 | | 2026-04-21 | 09:36 ET | [8-K](/filings/0001493152-26-018231.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-018231 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-014117.md), filed Mar 31, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/b468c99a-cf97-439c-8f21-91f2fb1ab2c1) ## About the filer - CIK: 855683 - Tickers: MLSS - Exchange: NYSE - SIC code: 3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.